Help! Please Register
All info 3fatchicks.com look on this site 3fatchicks.com
  Education &
  Tools

  Introduction
  Abbreviations
  Links
  CME
  Conference
   Highlights
  Bibliography
  Glossary
  Good Books
  Events Calendar


  Mycoses

  Introduction
  Human
  Veterinary
  Environmental
   Industrial
  Agricultural
  MSG


  The Fungi

  Introduction
  Descriptions
  Synonyms
  Image Bank
  Lecture Bank
  Video Bank


  Drugs

  Introduction
  Medical
  Veterinary
  Environmental
   Industrial
  Agricultural


  Laboratory

  Introduction
  Susceptibility
  MIC Database
  Procedures
  Histopathology


  About Us

  Introduction
  Our Mission
  Editorial Board
  Editorial Staff
  Supporters
  Contributors
  Legal Stuff
  Privacy Policy
  Kudos


  The Fungi

  Introduction
  Descriptions
  Synonyms
  Image Bank
  Lecture Bank
  Video Bank



This page updated:
1/27/2007 9:23:00 AM


DoctorFungus - All Rights Reserved © 2007 Copyright
& Privacy Policy


Site built and designed for doctorfungus by Webillustrated



You are here: Education & Tools >
Astellas Pharma Inc.

conference highlightsConference Highlights

Focus on Fungal Infections 13


Antifungal Agents
  1. PREVALENCE AND FLUCONAZOLE SUSCEPTIBILITY OF CANDIDA SPP. RECOVERED FROM THE OROPHARYNX OF HEALTH CARE WORKERS AND NON-HEALTH CARE
    Klein JD, Levin SM, Steele-Moore L, A.I. Dupont Hospital for Children,
    Wilmington, United States


  2. EPIDEMIOLOGY OF CLINICAL ISOLATES OF FLUCONAZOLE RESISTANT CANDIDA
    Piper J, Couch K, Steele-Moore L, Tuttle D, Christiana Care Health System,
    Newark, United States


  3. FLUCONAZOLE HETERORESISTANCE IN CANDIDA PARAPSILOSIS
    Yamazumi T, Toda H, Iimori M, Akita T, Kitatobe A, Furuta I,
    Kinki University, Osakasayama, Japan


  4. SUSCEPTIBILITY OF GLOBAL ISOLATES OF CANDIDA SPECIES TO FLUCONAZOLE AND VORICONAZOLE BY DISK DIFFUSION
    Sheehan DJ, Pfizer, New York, United States,
    The Global Surveillance Group, New York, United States


  5. ANTIFUNGAL AGENTS PROBABLY INFLUENCE THE CHANGE OF THE EPIDEMIOLOGY OF FUNGEMIA
    Yamakami Y, Tokimatsu I, Karashima R, Nagai H, Kadota J, Nasu M, Hiramatsu K, Saikawa T, Oita Medical University,
    Oita, Japan


  6. LOW DOSE LIPOSOMAL AMPHOTERICIN IS EFFECTIVE IN FUNGAL PREVENTION IN ALLOGENEIC STEM CELL TRANSPLANT
    Frame D, RUSH Medical Center, Chicago, United States,
    Samuel S, Hackensack University Medical Center, Hackensack, United States,
    Klingeman H, RUSH Medical Center, Chicago, United States,
    Kuyumjian A, Hackensack University Medical Center, Hackensack, United States,
    Cicogna C, Hackensack University Medical Center, Chicago, United States,
    Drajer D, RUSH Medical Center, Chicago, United States,
    Mecca K, Hackensack University Medical Center, Hackensack, United States,
    Myint H, RUSH Medical Center, Chicago, United States


  7. AMPHOTERICIN B FOR THE TREATMENT OF SYSTEMIC FUNGAL INFECTIONS: A META-ANALYSIS OF CONVENTIONAL VERSUS LIPID FORMULATIONS
    MacAulay SS, London Health Sciences Centre, London,
    Canada, Martin JE, Lawson Health Research Institute, London, Canada,
    Zarnke KB, University of Western Ontario, Ontario, Canada


  8. MICAFUNGIN (MCFG), AN ECHINOCANDIN ANTIFUNGAL AGENT FOR THE TREATMENT OF NEW AND REFRACTORY CANDIDEMIA
    Ostrosky-Zeichner L, UT Houston Medical School, Houston, United States,
    Anaissie E, University of Arkansas, Little Rock, United States,
    Kontoyiannia D, UT Houston Medical School, Houston, United States,
    Rex JH, UT Houston Medical School, Houston, United States,
    Raffalli J, UT Houston Medical School, Houston, United States,
    Buell DN, UT Houston Medical School, Houston, United States,
    Mullane KM, UT Houston Medical School, Houston, United States,
    Vazquez J, UT Houston Medical School, Houston, United States


  9. AZOLE TREATMENT OF TWO UNUSUAL PATHOGENS
    Durham H, Baumgarten K, Ochsner Clinic Foundation,
    New Orleans, United States


  10. CASPOFUNGIN (CSP): WHAT MEASURES RESISTANCE?
    Hernandez S, Najvar L, Lopez-Ribot J, McCarthy D, Bocanegra R, Graybill JR, UT Health Sciences Center,
    San Antonio, United States


  11. CLINICAL EXPERIENCE OF CASPOFUNGIN AND CYCLOSPORIN A (CsA) IN PATIENTS TREATED IN CASPOFUNGIN CLINICAL TRIALS
    Kartsonis N, Ngai A, Ryan D, Sable C, Merck Research Laboratories, Blue Bell,
    PA, United States


  12. NOVEL ANTIFUNGAL USE IN AN INNER CITY HOSPITAL, A COMPARISON BETWEEN CASPOFUNGIN AND VORICONAZOLE
    Gunderson SM, Danziger LH, University of Illinois at Chicago,
    Chicago, United States


  13. IN VITRO AND IN VIVO ACTIVITY OF ALBACONAZOLE
    Alguero M, Merlos M, Boncompte, Bartroli J, R & D Center,
    Barcelona, Spain


  14. LACK OF QTC EFFECTS OF ALBACONAZOLE, A NEW TRIAZOLE ANTIFUNGAL
    De La Cruz G, Perez I, Giral M, Bartroli J, Zquierdo I, Merlos M, R & D Center,
    Barcelona, Spain


  15. A NOVEL SMALL MOLECULE ANTIFUNGAL COMPOUND WITH IN VIVO ACTIVITY AGAINST ASPERGILLUS FUMIGATUS
    Velligan MD, Genelabs Technologies Inc., Redwood City, United States,
    Clemons KV, Singh G, Stevens DA, Santa Clara Valley Medical Center and Stanford University, San Jose and Stanford , United States,
    Li WB, Botyanszki P, Roberts C, Shi DF, Lou L, Griffith RC, Genelabs Technologies Inc., Redwood City, United States


  16. GLYCOSYL AMINO ACID DERIVATIVES AS INHIBITOR OF DNA TOPOISOMERASE I OF CANDIDA ALBICANS
    Khan ZK, Jain P, Tripathi RP, Tekwani BL, Central Drug Research,
    Philadelphia, United States


  17. AMPHOTERICIN B EFFICACY IN THE ACUTE PHASE OF PARACOCCIDIOIDOMYCOSIS: LESSONS FROM A MURINE MODEL
    Scavone R, Burger E, Universidade de Sao Paulo,
    Sao Paulo, Brazil


top of page    




View other categories
Antifungal Agents | Antifungal Combinations | Basic Mycology | Case Reports
Clinical Mycology | Animal Models | Diagnostics | Miscellaneous | View All





  Home | Image Bank | Lecture Bank | Knowledgebase | Site Map | Contact Us |
The Fungi | Mycoses | Drugs |
Laboratory | Education & Tools | About Us

  bttm_banner_indv2_02[1].gif